Why Cue Biopharma, Inc.’s (CUE) Stock Is Down 11.49%
As of Thursday, November 05, Cue Biopharma, Inc.’s CUE share price has dipped by 11.49%, which has investors questioning if this is right time to buy.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company’s lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company’s lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Commentary & Analysis
Why Cue Biopharma, Inc.’s (CUE) Stock Is Down 7.36%
As of Wednesday, November 04, Cue Biopharma, Inc.’s CUE share price has dipped by 7.36%, which has investors questioning if this is right time to buy.Michael Rose
Why Cue Biopharma, Inc.’s (CUE) Stock Is Up 5.87%
As of Tuesday, November 03, Cue Biopharma, Inc.’s CUE share price has surged by 5.87%, which has investors questioning if this is right time to sell.Michael Rose
Why Cue Biopharma, Inc.’s (CUE) Stock Is Down 7.13%
As of Friday, October 30, Cue Biopharma, Inc.’s CUE share price has dipped by 7.13%, which has investors questioning if this is right time to buy.Michael Rose
Why Cue Biopharma, Inc.’s (CUE) Stock Is Up 6.83%
As of Wednesday, October 28, Cue Biopharma, Inc.’s CUE share price has surged by 6.83%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | CUE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $130.9 | $214.3 | 25% |
|
| Shares Out (Mil) | 6.3 | 53.9 | 16% |
|
| Institutional Ownership | 75.6% | 92.9% | 46% |
|
| Float (Mil) | 6.4 | 41.4 | 14% |
|
| Beta | 2.47 | 0.96 | 96% |
|
| Avg Daily Volume (000s) | 132 | 506 | 40% |
|
| Price Change (52-week) |
(16.7%) | 43.9% | 37% |
|
| Growth | CUE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 53.8% | 13.2% | 96% |
|
| Net Income (5yr) | 9.9% | (10.1%) | 55% |
|
| EPS (5yr) | 29.0% | 15.8% | 80 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (45.9%) | (15.7%) | 9% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | CUE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $38 | $37 | 18% |
|
| Net Income (TTM) (Mil) | ($164) | ($44) | 8% |
|
| EPS (TTM) | ($36.222) | ($1.500) | 2% |
|
| Operating Cash Flow (TTM) (Mil) | ($50) | ($34) | 10% |
|
| Net Cash Flow (TTM) (Mil) | ($10) | $1 | 31% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 18% |
|
| Enterprise Value (Q1) (Mil) | $160 | $172 | 25% |
|
| Valuation | CUE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 40.97 | 2.00 | 98% |
|
| P/E | na | 18.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | CUE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (99.2%) | 67.3% | 2% |
|
| Net Margin | (435.8%) | (63.5%) | 2% |
|
| ROA | (459.6%) | (47.5%) | 0% |
|
| ROE | na | (53.3%) | na |
|
| Liabilities to Assets | 92.5% | 29.6% | 90% |
|
| F-Score | 4 | 2 | 33% |
|
Cue Biopharma, Inc. did not pass any screens on 11/5/2026.
